NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOVIST II is a diatrizoate meglumine injectable contrast agent used in diagnostic imaging procedures. It is a small-molecule radiographic contrast medium that enhances visualization of internal structures during X-ray and fluoroscopic examinations. The drug has been a foundational diagnostic imaging tool since its approval in 1955.
LOE Approaching
With LOE approaching and modest competitive pressure (30%), the brand team is likely smaller and focused on defensive strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENOVIST II offers limited career advancement opportunities given its mature, LOE-approaching lifecycle and minimal linked job openings. Roles on this product are primarily focused on compliance, market maintenance, and stakeholder relationship management rather than innovation or growth.
Regulatory Affairs SpecialistProduct Manager
Worked on RENOVIST II at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.